Here is the detailed information for:
💊 Tenofovir Alafenamide Fumarate (TAF) Tablet 25 mg
🧪 Composition:
- Each tablet contains:
Tenofovir Alafenamide Fumarate, equivalent to Tenofovir Alafenamide 25 mg
🌐 Therapeutic Class:
- Antiviral (Nucleoside Reverse Transcriptase Inhibitor – NRTI)
- Used in treatment of HIV-1 and Chronic Hepatitis B
✅ Indications / Uses:
- HIV-1 infection (in combination with other antiretrovirals):
- Adults and adolescents (age ≥12 years, weight ≥35 kg)
- Chronic Hepatitis B virus (HBV) infection:
- Adults with compensated liver disease
⚖️ Dosage:
- HIV Treatment:
- Often used in fixed-dose combinations (e.g., with Emtricitabine and/or Dolutegravir)
- Standalone TAF 25 mg may be used with other antiretrovirals if appropriate
- Hepatitis B:
- TAF 25 mg once daily, with food
⚠️ Precautions:
- Renal function:
- Better renal and bone safety profile than TDF (Tenofovir Disoproxil Fumarate)
- Monitor serum creatinine and phosphate periodically
- Hepatic impairment:
- Not recommended in decompensated liver disease
- Risk of HBV exacerbation if therapy is stopped abruptly
- Drug interaction potential:
- Avoid use with rifampin, carbamazepine, or other strong P-gp inducers
🚫 Contraindications:
- Known hypersensitivity to Tenofovir alafenamide
- Concurrent use with strong P-gp inducers (reduces TAF levels)
💥 Common Side Effects:
- Headache
- Nausea
- Fatigue
- Abdominal pain
- Elevated liver enzymes
- Decreased bone mineral density (less than TDF)
👩⚕️ Use in Special Populations:
- Pregnancy: Generally considered safe (category B)
- Lactation: Caution advised
- Children: Approved for age ≥12 years (some lower-dose formulations for pediatrics exist)
📦 Storage:
- Store below 30°C, in original container
- Protect from moisture